The Asia Pacific Sepsis Diagnostics Market would witness market growth of 9.3% CAGR during the forecast period (2022-2028).
Current sepsis diagnosis approaches are based on non-specific physiological and clinical parameters, making it difficult to differentiate sepsis from a systemic inflammatory response induced by normal inflammation. The preliminary test for infection, coagulation and reduced oxygen availability is a blood test, Urine wound secretions, and respiratory secretions are among the other tests that are performed. If these tests fail to diagnose sepsis and identify the site of inflammation, X-rays, Magnetic Resonance Imaging, Computerized Tomography, and Ultrasound are performed.
The rising number of hospital-acquired infections (HAIs) that cause sepsis, especially among the elderly, babies, and patients with chronic illnesses, is increasing the demand for sepsis diagnostics. Further, the increased prevalence of a variety of infectious disorders caused by antibiotic-resistant bacteria, including both gram-positive and gram-negative bacteria, is driving the demand for sepsis diagnostics. Furthermore, the rising healthcare sector, combined with the growing use of modern data analytics technologies and , a rise in the number of drugs approved for sepsis diagnosis, is propelling the market forward.
There are several developing countries across this region, due to which, these countries are majorly investing on the enhancement of their healthcare infrastructure. For example, china and India are observing rapid economic development and innovation in the medical system. Moreover, due to the high death rate linked with sepsis disease, the necessity for sepsis diagnostics is likely to increase. In addition, increased awareness of sepsis monitoring and diagnosis in the region's countries is likely to minimize the disease's negative effects. This is due to an increase in the demand for sepsis diagnostic treatments in countries with high rates of infectious illnesses. The expansion of the regional market is also owing to an increase in regional activities to expand access to breakthrough laboratory automation systems.
The China market dominated the Asia Pacific Sepsis Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2018; thereby, achieving a market value of $69.5 million by 2028. The Japan market is experiencing a CAGR of 8.6% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 9.9% during (2022 - 2028).
Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Sepsis Diagnostics MarketMarket is Projected to reach USD 879.5 Million by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
By Method
By Test Type
By Pathogen
By Product
By End-User
By Technology
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 